Inovio completes enrollment of VGX-3100 phase 2 trial for treatment of HPV-related VIN
Inovio announced it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia. VGX-3100 is an immunotherapy that targets HPV 16 and 18 and is being studied for treatment of HPV-related precancerous lesions. July 08, 2019